IL2 and systemic lupus erythematosus: Although clinical trials suggested that LD‐IL‐2 therapy is capable of promoting the selective expansion of a functionally competent Treg population in a well‐tolerated way and may have the potential to influence the clinical course in patients with active SLE, evidence‐based medicine evidence is inadequate, with low sample sizes and limited elaboration, no systematic data to comprehensively explain its safety, effectiveness and the optimal dosage of LD‐IL‐2 (1 million IU every other day or 0.5 million IU per day).8, 9